Another study focused on the administration of erlotinib in resistant EGFR-mutated NSCLC and used NPs such as poly (ethylene glycol)-poly (lactic acid) (PEG-PLA NPs) for the co-delivery of erlotinib and fedratinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.